A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of siponimod along with influenza and pneumococcal (PPV-23) vaccine in healthy volunteers
Latest Information Update: 04 May 2016
At a glance
- Drugs Siponimod (Primary) ; Influenza virus vaccine; Pneumococcal vaccine
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Novartis
- 04 May 2016 New trial record
- 21 Apr 2016 Results of effect of siponimod treatment on vaccination-induced immune response (n=136) were presented at the 68th Annual Meeting of the American Academy of Neurology.